{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:42:29Z","timestamp":1792284149485,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Jiaxing Science and Technology Programme","award":["No. 2025CGW136"],"award-info":[{"award-number":["No. 2025CGW136"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10096-026-05584-4","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:42:09Z","timestamp":1783604529000},"page":"3159-3167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Performance evaluation of antimicrobial susceptibility testing methods for ceftazidime-avibactam and imipenem-relebactam against Klebsiella pneumoniae and Pseudomonas aeruginosa"],"prefix":"10.1007","volume":"45","author":[{"given":"Xiaobo","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erjie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"5584_CR1","volume-title":"WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance","author":"World Health Organization","year":"2024","unstructured":"World Health Organization (2024) WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. World Health Organization, Geneva"},{"issue":"10","key":"5584_CR2","doi-asserted-by":"publisher","first-page":"E716","DOI":"10.3390\/antibiotics9100716","volume":"9","author":"X Zhen","year":"2020","unstructured":"Zhen X, St\u00e5lsby Lundborg C, Sun X, Gu S, Dong H (2020) Clinical and Economic Burden of Carbapenem-Resistant Infection or Colonization Caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: A Multicenter Study in China. Antibiot (Basel) 9(10):E716. https:\/\/doi.org\/10.3390\/antibiotics9100716","journal-title":"Antibiot (Basel)"},{"key":"5584_CR3","doi-asserted-by":"publisher","first-page":"1231740","DOI":"10.3389\/fcimb.2023.1231740","volume":"13","author":"A Sophonsri","year":"2023","unstructured":"Sophonsri A, Kelsom C, Lou M, Nieberg P, Wong-Beringer A (2023) Risk factors and outcome associated with coinfection with carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumanii: a descriptive analysis. Front Cell Infect Microbiol 13:1231740. https:\/\/doi.org\/10.3389\/fcimb.2023.1231740","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"5584_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/ijms27031229","volume":"27","author":"A Elbehiry","year":"2026","unstructured":"Elbehiry A, Marzouk E, Abalkhail A (2026) Molecular Insights into Carbapenem Resistance in Klebsiella pneumoniae: From Mobile Genetic Elements to Precision Diagnostics and Infection Control. Int J Mol Sci 27(3):1229. https:\/\/doi.org\/10.3390\/ijms27031229","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5584_CR5","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1128\/CMR.00040-09","volume":"22","author":"PD Lister","year":"2009","unstructured":"Lister PD, Wolter DJ, Hanson ND (2009) Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 22(4):582\u2013610. https:\/\/doi.org\/10.1128\/CMR.00040-09","journal-title":"Clin Microbiol Rev"},{"issue":"Suppl 7","key":"5584_CR6","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y (2019) Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis 69(Suppl 7):S565\u2013S575. https:\/\/doi.org\/10.1093\/cid\/ciz830","journal-title":"Clin Infect Dis"},{"issue":"1","key":"5584_CR7","doi-asserted-by":"publisher","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","volume":"34","author":"D Yahav","year":"2020","unstructured":"Yahav D, Giske CG, Gr\u0101matniece A, Abodakpi H, Tam VH, Leibovici L (2020) New \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combinations. Clin Microbiol Rev 34(1):e00115\u2013e00120. https:\/\/doi.org\/10.1128\/CMR.00115-20","journal-title":"Clin Microbiol Rev"},{"key":"5584_CR8","doi-asserted-by":"publisher","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA (2024) Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin Infect Dis. 2024:ciae403. https:\/\/doi.org\/10.1093\/cid\/ciae403","DOI":"10.1093\/cid\/ciae403"},{"issue":"1","key":"5584_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M et al (2018) Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-\u03b2-Lactamase Inhibitor Combinations. Drugs 78(1):65\u201398. https:\/\/doi.org\/10.1007\/s40265-017-0851-9","journal-title":"Drugs"},{"key":"5584_CR10","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1093\/jac\/dkaf332","volume":"80","author":"I Morrissey","year":"2025","unstructured":"Morrissey I, Patel JB (2025) Modification of antimicrobial susceptibility testing methods. J Antimicrob Chemother 80:2887\u20132888. https:\/\/doi.org\/10.1093\/jac\/dkaf332","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"5584_CR11","doi-asserted-by":"publisher","first-page":"e0016625","DOI":"10.1128\/spectrum.00166-25","volume":"13","author":"TY Kim","year":"2025","unstructured":"Kim TY, Baek JY, Suh E, Lee J, Yu H, Ko J et al (2025) Evaluation of the VITEK 2 AST-N439 card for susceptibility testing of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and colistin in carbapenem-non-susceptible gram-negative bacilli. Microbiol Spectr 13(10):e0016625. https:\/\/doi.org\/10.1128\/spectrum.00166-25","journal-title":"Microbiol Spectr"},{"issue":"8","key":"5584_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jmoldx.2021.05.009","volume":"23","author":"Z Liu","year":"2021","unstructured":"Liu Z, Bai L, Liu J, Lei J, Gao XH, Tenover FC et al (2021) Parallel Validation of the NG-Test Carba 5 and the Xpert Carba-R for Detection and Characterization of Carbapenem-Resistant Enterobacterales Causing Bloodstream Infections[J]. J Mol Diagn 23(8):1007\u20131014 https:\/\/doi.org\/10.1016\/j.jmoldx.2021.05.009","journal-title":"J Mol Diagn"},{"key":"5584_CR13","unstructured":"Clinical and Laboratory Standards Institute (2024) Performance standards for antimicrobial susceptibility testing. 34th ed. CLSI supplement M100. Clinical and Laboratory Standards Institute"},{"issue":"4","key":"5584_CR14","doi-asserted-by":"publisher","first-page":"106633","DOI":"10.1016\/j.ijantimicag.2022.106633","volume":"60","author":"SS Kanj","year":"2022","unstructured":"Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y et al (2022) Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 60(4):106633. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106633","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"5584_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s15010-021-01735-1","volume":"50","author":"S Maraki","year":"2022","unstructured":"Maraki S, Mavromanolaki VE, Magkafouraki E, Moraitis P, Stafylaki D, Kasimati A et al (2022) Epidemiology and in vitro activity of ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates. Infection 50(2):467\u2013474. https:\/\/doi.org\/10.1007\/s15010-021-01735-1","journal-title":"Infection"},{"issue":"4","key":"5584_CR16","doi-asserted-by":"publisher","first-page":"e02209","DOI":"10.1128\/AAC.02209-16","volume":"61","author":"SH Lob","year":"2017","unstructured":"Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA et al (2017) In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob Agents Chemother 61(4):e02209\u2013e02216. https:\/\/doi.org\/10.1128\/AAC.02209-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"5584_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","volume":"13","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785\u2013796. https:\/\/doi.org\/10.1016\/S1473-3099(13)70190-7","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5584_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1099\/jmm.0.001142","volume":"69","author":"SH Lob","year":"2020","unstructured":"Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Sahm DF (2020) In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples- SMART Surveillance Europe 2015\u20132017. J Med Microbiol 69(2):207\u2013217. https:\/\/doi.org\/10.1099\/jmm.0.001142","journal-title":"J Med Microbiol"},{"issue":"1","key":"5584_CR19","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s42003-024-07337-5","volume":"7","author":"Y Li","year":"2024","unstructured":"Li Y, Yang Q, Chen M, Cai H, Fang L, Zhou J et al (2024) Decadal Evolution of KPC-related plasmids in Pseudomonas aeruginosa high-risk clone ST463 in Zhejiang, China. Commun Biol 7(1):1646. https:\/\/doi.org\/10.1038\/s42003-024-07337-5","journal-title":"Commun Biol"},{"key":"5584_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/14787210.2025.2473047","volume":"23","author":"K Bush","year":"2025","unstructured":"Bush K (2025) Past, present, and future perspectives on aztreonam and avibactam. Expert Rev Anti Infect Ther 23:277\u2013290. https:\/\/doi.org\/10.1080\/14787210.2025.2473047","journal-title":"Expert Rev Anti Infect Ther"},{"key":"5584_CR21","doi-asserted-by":"publisher","first-page":"e207925","DOI":"10.1128\/spectrum.02079-25","volume":"13","author":"JH Kimbrough","year":"2025","unstructured":"Kimbrough JH, Karr MH, Nguyen ST, DeJonge BLM, Longshaw C, Takemura M et al (2025) Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020\u20132023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program. Microbiol Spectr 13:e207925. https:\/\/doi.org\/10.1128\/spectrum.02079-25","journal-title":"Microbiol Spectr"},{"issue":"5","key":"5584_CR22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/antibiotics12050892","volume":"12","author":"KM Papp-Wallace","year":"2023","unstructured":"Papp-Wallace KM, Barnes MD, Taracila MA, Bethel CR, Rutter JD, Zeiser ET et al (2023) The Effectiveness of Imipenem-Relebactam against Ceftazidime-Avibactam Resistant Variants of the KPC-2 \u03b2-Lactamase. Antibiot (Basel) 12(5):824. https:\/\/doi.org\/10.3390\/antibiotics12050892","journal-title":"Antibiot (Basel)"},{"issue":"4","key":"5584_CR23","doi-asserted-by":"publisher","first-page":"e0112024","DOI":"10.1128\/aac.01120-24","volume":"68","author":"T Blanco-Mart\u00edn","year":"2024","unstructured":"Blanco-Mart\u00edn T, Gonz\u00e1lez-Pinto L, Aja-Macaya P, Rodr\u00edguez-Pallares S, S\u00e1nchez-Pe\u00f1a L, Gato E et al (2024) Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem\/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime\/avibactam resistance. Antimicrob Agents Chemother 68(4):e0112024. https:\/\/doi.org\/10.1128\/aac.01120-24","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"5584_CR24","doi-asserted-by":"publisher","first-page":"e0091822","DOI":"10.1128\/aac.00918-22","volume":"66","author":"J Findlay","year":"2022","unstructured":"Findlay J, Rens C, Poirel L, Nordmann P (2022) In Vitro Mechanisms of Resistance Development to Imipenem-Relebactam in KPC-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother 66(5):e0091822. https:\/\/doi.org\/10.1128\/aac.00918-22","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"5584_CR25","doi-asserted-by":"publisher","first-page":"106660","DOI":"10.1016\/j.ijantimicag.2022.106660","volume":"60","author":"RA Bonnin","year":"2022","unstructured":"Bonnin RA, Bernabeu S, Emeraud C, Creton E, Vanparis O, Naas T et al (2022) Susceptibility of OXA-48-producing Enterobacterales to imipenem\/relebactam, meropenem\/vaborbactam and ceftazidime\/avibactam. Int J Antimicrob Agents 60(4):106660. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106660","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"5584_CR26","doi-asserted-by":"publisher","first-page":"e00695","DOI":"10.1128\/JCM.00695-20","volume":"58","author":"H Hakvoort","year":"2020","unstructured":"Hakvoort H, Bovenkamp E, Greenwood-Quaintance KE, Schmidt-Malan SM, Mandrekar JN, Schuetz AN, Patel R (2020) Imipenem-Relebactam Susceptibility Testing of Gram-Negative Bacilli by Agar Dilution, Disk Diffusion, and Gradient Strip Methods Compared with Broth Microdilution. J Clin Microbiol 58(10):e00695\u2013e00620. https:\/\/doi.org\/10.1128\/JCM.00695-20","journal-title":"J Clin Microbiol"},{"issue":"5","key":"5584_CR27","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1007\/s10096-025-05058-z","volume":"44","author":"A Biguenet","year":"2025","unstructured":"Biguenet A, Devoos L, Rousselot J, Bour M, Fournier D, Jeannot K (2025) Evaluation of imipenem-relebactam susceptibility testing in carbapenem resistant Pseudomonas aeruginosa: comparison of sensititre microplates, disc diffusion, and MTS gradient strips with broth microdilution. Eur J Clin Microbiol Infect Dis 44(5):1231\u20131237. https:\/\/doi.org\/10.1007\/s10096-025-05058-z","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"5584_CR28","doi-asserted-by":"publisher","first-page":"e01129","DOI":"10.1128\/JCM.01129-19","volume":"57","author":"G Kahlmeter","year":"2019","unstructured":"Kahlmeter G, Giske CG, Kirn TJ, Sharp SE (2019) Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results. J Clin Microbiol 57(11):e01129\u2013e01119. https:\/\/doi.org\/10.1128\/JCM.01129-19","journal-title":"J Clin Microbiol"},{"key":"5584_CR29","unstructured":"The European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0. 2025. Available at: https:\/\/www.eucast.org\/clinical_breakpoints"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05584-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05584-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:02:51Z","timestamp":1792281771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05584-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["5584"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05584-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study and the funded project were reviewed by the Medical Ethics Committee of Zhejiang Rongjun Hospital.","order":1,"name":"Ethics","label":"Ethical compliance","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}